By Jason Spangler, MD, MPH, FACPM (CEO, Innovation and Value Initiative)
In March, the Centers for Medicare and Medicaid Services (CMS) released draft guidance for its implementation of the Drug Price Negotiation Program (DPNP), a key component of the Inflation Reduction Act (IRA). This release and its associated comment period sparked far-ranging debate and a stream of news articles, conference panels, and position statements on how the agency can improve its processes and implementation. Perspectives on these issues are as diverse as the voices weighing in. The one matter they all seem to assume is that CMS is interested in value, defined as the improvement of health outcomes per the costs needed to do so, both for their beneficiaries and the other stakeholders involved. This thinking has not changed with the release of the revised guidance in June…
Read the full article here.
The Innovation and Value Initiative (IVI) is a 501(c)(3) tax-exempt, non-profit research organization dedicated to advancing the science and improving the practice of health technology assessment through development of novel methods and the creation and application of enhanced health technology assessment models to support local decision-making needs in healthcare.
Contact: Smita Sanwardeker
E-Mail: [email protected]